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Abstract
Non-inferiority trials test whether a new product is not unacceptably worse than a product already in use. This
paper introduces concepts related to non-inferiority, and discusses the regulatory views of both the European
Medicines Agency and the United States Food and Drug Administration.
Introduction
‘Well, in our country,’ said Alice, still panting a little,
‘you’d generally get to somewhere else - if you ran very
fast for a long time as we’ve been doing.’
‘A slow sort of country!’ said the Queen. ‘Now, here,
you see, it takes all the running you can do, to keep in
the same place. If you want to get somewhere else, you
must run at least twice as fast as that!’
Lewis Carroll, Through the Looking Glass
Classical statistics is non-intuitive enough when you are
trying to show that a new intervention is better than a pre-
vious one. You cannot prove what you want to prove; all
you can say is that the data you observe provide sufficient
evidence to reject the hypothesis that the two interven-
tions have the same effect. Then, when you try to estimate
the magnitude of the effect, all you can say is that if you
repeated your experiment an infinite number of times and
calculated your confidence interval (CI) as you were
taught, 95% of those intervals would cover the true effect.
(No wonder people flee to Bayesian inference!) But as diffi-
cult and counterintuitive as classical statistics may be, they
are simple compared with the problems of inference in
non-inferiority trials.
When designing a trial to show superiority of a new
intervention, you specify a null hypothesis; consistent with
the word ‘null’, your hypothesis asserts that the two inter-
ventions are the same. You then choose an alternative
hypothesis stating that the difference between the means,
or some other statistic, is g. Throughout this paper, we
assume that larger positive outcomes are better than smal-
ler positive outcomes, and a positive treatment difference,
g, provides evidence of benefit. For situations in which a
smaller outcome is better than a larger outcome (for
example, tumor size in cancer applications) the signs in
this paper would change from negative to positive. You
use your chosen Type I error rate or a, your desired
power, and g to select your sample size. The goal of your
experiment is to reject that null hypothesis, thus g is in
some sense a tool to help you select your sample size. At
the end of the trial, the estimated effect may be bigger or
smaller than g, but as long as the lower bound of your 95%
CI is above zero, you may reject your null hypothesis. The
preselected g plays no formal statistical role in the analysis
of a superiority trial, although the difference in magnitude
between the hypothesized g a n dt h ee s t i m a t e de f f e c ti s
likely to influence how to interpret the results.
A non-inferiority experiment, by contrast, tries to show
that the new intervention is not ‘inferior’ to the previous
one, or, more precisely, that the new intervention is ‘not
unacceptably worse’ than the intervention used as the con-
trol. Thus the null hypothesis seems backwards, in a sense,
as this hypothesis is not ‘null’ at all. Instead, it states that
the new treatment is worse than the old by more than -Δ,
where -Δ is the ‘non-inferiority margin’. The alternative
hypothesis states that the difference in the effect between
the new and old interventions is less than -Δ (Figure 1). In
the inverted world of non-inferiority, the alternative
hypothesis seems ‘null’, whereas the null hypothesis
includes a specified treatment difference of -Δ. Here, -Δ is
an integral part not only of the design, as with g in super-
iority trials, but of the analysis as well, a role that g does
not play in superiority trials.
Reversing the null and alternative hypotheses may be
the first looking-glass problem of non-inferiority, but as
we peer deeper, the backwardness seems to multiply!
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investigator (although not always; improper handling of
missing data can benefit a more toxic, less efficacious
treatment, potentially increasing the possibility of a false
finding in a superiority trial). By contrast, non-inferiority
trials tend to reward the careless. The less rigorously
conducted the trial, the easier it can be to show non-
inferiority. As treatments improve, showing benefit of a
new therapy becomes more and more difficult, but show-
ing non-inferiority becomes ever easier, stemming from
‘lack of constancy’ (deliciously termed ‘biocreep’ in drugs
and ‘technocreep’ in devices). But wait! There’sm o r e !
Non-inferiority trials also face the issue of ‘assay sensitiv-
ity’, the reality that, in some disease settings, even truly
effective drugs do not always show benefit in a clinical
trial. This means that a non-inferiority trial in a setting in
which the standard drug would not have been shown
superior to placebo would be likely to demonstrate non-
inferiority of the new treatment (see [1,2] for further dis-
cussions of assay sensitivity and other issues related to
active controlled trials).
For all these reasons and probably several more, many
investigators faced with the challenge of designing and
interpreting non-inferiority trials often despair when try-
ing to understand them. In this commentary, we explain
what a non-inferiority trial attempts to show; we amplify
some of the problems discussed above; we distinguish
the regulatory view of the US Food and Drug Adminis-
tration (FDA) from that of the European Medicines
Agency (EMA); and, perhaps, most important, we dis-
cuss why such trials are often desirable to perform.
Superiority, equivalence, and non-inferiority
Investigators understand intuitively, even before apply-
ing statistical rigor, how to conduct a trial to establish
superiority of a novel treatment. When a new therapy is
compared with a placebo control, or, if one exists, an
active control, the investigator defines an outcome (such
as level of pain or overall survival) and declares the new
treatment superior if, at the end of the trial, the esti-
mated value of the outcome in the treated group is ‘bet-
ter’ than the estimate in the control group. Statistically
speaking, ‘better’ means that the data allow rejection of
the null hypothesis that the two distributions are equal,
in favor of the hypothesis that the new treatment is bet-
ter than the control.
Sometimes, the goal is not to show that the new treat-
ment is better, but that the new treatment is ‘equivalent’
to the control. Because only with an infinite sample size
would it be possible to show exact equivalence, investi-
gators instead select a margin. Again, call it Δ.A tt h e
end of the trial, a CI is computed around the difference
between two test statistics (equivalence trials typically
use 90% CIs) and if the CI lies strictly within [-Δ,+ Δ]
the two treatments are called ‘equivalent.’ Such trials are
used to show that a generic drug is biologically the
same as the drug it is trying to mimic. They are also
used to show lot consistency in vaccine trials, in which
the outcome is a measure of immune response.
Non-inferiority is different from equivalence. In an
equivalence trial, the desired conclusion is that two pro-
ducts are the same or ‘not unacceptably different’ from
each other. In a non-inferiority trial, by contrast, the
aim is to show that a new product is not unacceptably
worse than an older one. Why might it be reasonable to
pursue a product that is possibly less efficacious than an
existing therapy? A new treatment that is not much
worse than, or ‘non-inferior to’, the standard treatment
may be attractive if, when compared with the standard
treatment, it is expected to cause fewer side effects, or
lead to improved quality of life, or if its dosing regimen
is easier to tolerate.
Figure 1 The role of Δ in superiority, equivalence and non-inferiority trials.
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worse’ means (think of this as a window of indistin-
guishability, or a margin that we will call -Δ;b e l o ww e
discuss how to choose such a margin), and that there is
an existing treatment available against which to compare
the new treatment. The new treatment could be said to
be not unacceptably worse than [3] (that is, non-inferior
to) the existing treatment if, when the CI around the
difference in the effect size between the new and exist-
ing treatments is calculated, the lower bound of that
interval does not extend beyond the window of indistin-
guishability defined above. One focuses on the lower
bound for this non-inferiority comparison; what happens
at the upper end of the CI is not the primary concern.
In an equivalence trial, by contrast, investigators care
about both ends of the CI, and would declare the new
treatment equivalent to the existing treatment only if
the entire CI falls within this margin on either side of
zero.
Non-inferiority trials are clearly appropriate for some
diseases and some treatments. When developing a new
treatment to prevent tuberculosis, investigators might be
willing to sacrifice some small amount of benefit (as
reflected in the margin) for a simpler dosing schedule,
fewer side effects, or other advantages, but they would
be delighted if the new treatment were better than cur-
rent therapies (hence no restriction on the upper bound
of the interval) and they could also declare superiority.
This would only happen if the lower bound of the inter-
val were above zero, not simply above -Δ.
Thus far, the problem sounds straightforward. One
needs to select a non-inferiority margin, run the trial
comparing the experimental treatment to an active con-
trol, calculate the CI around the difference between the
treatments, and examine the lower bound of the CI. If
the lower bound is above the margin -Δ, the new treat-
ment is deemed non-inferior, and the trial is a ‘success’.
Further, if the new treatment is statistically significantly
better than the comparator (that is, the lower bound of
that same CI is also above zero), then superiority of the
new treatment can also be declared. Importantly, testing
first for non-inferiority and then for superiority does not
require a statistical ‘penalty’ for multiple testing, because
testing first for non-inferiority before testing for superior-
ity (while examining a single CI) uses a testing procedure
that appropriately controls the overall Type I, or a,e r r o r
rate of the two tests. Statisticians refer to this type of test-
ing as ‘closed testing’, and such a process ensures that the
overall experiment-wise error rate is maintained at the
correct level when testing more than one hypothesis. The
order of the testing is important; to declare superiority, a
new treatment necessarily also has to be declared non-
inferior. The converse (testing first for superiority and
then for non-inferiority) is not always a closed procedure.
Testing in that order could lead to apparently anomalous
results, even when examining a single CI. A large trial
with a narrow CI around the difference between the
active control and the new treatment might show that
the lower limit of the interval lies within the margin,
meaning that the new treatment is non-inferior to the
active control, but the upper limit of the interval is below
zero, so the new treatment is also inferior to the active
control. Bear in mind that the opposite of ‘non-inferior’
is not ‘inferior’; it is the looking-glass opposite, ‘not non-
inferior’.A sa ne x a m p l e ,s u p p o s et h em a r g i n- Δ is -3,
and the observed 95% CI at the end of the trial is [-2.7,
1 . 5 ] .T h el o w e rl i m i to ft h eC Ii sa b o v e- 3 ,s ot h en e w
drug is non-inferior to the old, but the upper limit of -1.5
is less than zero, so the new drug is also inferior to the
old. In this case, the single CI can be used to say that the
new treatment is simultaneously ‘non-inferior’ and ‘infer-
ior’. Although this example may seem counterintuitive,
when interpreting the results of a non-inferiority trial, it
must be remembered that the purpose of the trial is to
estimate the lower bound of the CI, not to establish a
point estimate of the treatment effect. This test, sitting
on the other side of the looking glass, requires an inter-
pretation different from the usual.
In some trials, it is statistically appropriate to perform
a superiority comparison first and, if that does not show
statistical benefit, to perform a non-inferiority compari-
son. That would be appropriate only when the non-
inferiority margin had been preselected. The reason
such a switch is permissible stems from the fact that we
can view the test as an interpretation of a CI. The calcu-
lated CI does not know whether its purpose is to judge
superiority or non-inferiority. If it sits wholly above
zero, then it has shown superiority. If it sits wholly
above -Δ, then it has shown non-inferiority.
A non-inferiority trial can have five possible types of
outcomes as depicted in Figure 2. The two vertical lines
indicate zero and -Δ. Each horizontal line represents a
CI, with the estimated treatment effect denoted by the
dot in the center. The CI at the top of the figure sits
wholly above zero; a trial with this outcome would con-
clude that the new treatment is superior and hence,
also non-inferior, to the control. The next interval,
which spans zero but lies wholly above -Δ,r e p r e s e n t sa
trial that has shown non-inferiority, but not superiority.
The third interval, which straddles both zero and -Δ,
represents a trial that has shown neither non-inferiority
nor superiority. The fourth CI illustrates the case dis-
cussed above; tucked between the two vertical lines, it
shows both non-inferiority (because it lies wholly above
t h el i n ef o r- Δ)a n di n f e r i o r i t y( b e c a u s ei ta l s ol i e s
wholly below zero). The final CI on the bottom of the
figure shows inferiority and does not show non-
inferiority.
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Among the challenges in non-inferiority trials compared
with superiority trials are the choices of the margin, the
primary population for analysis, and the comparator
treatment. As in our previous section, we delay discus-
sion of the margin and tackle the latter problems first.
Conventional wisdom suggests that in a non-inferior-
ity trial, the primary population for analysis should be
the per-protocol (PP) population, which in this case is
the set of people who have taken their assigned treat-
ment and adhered to it. (Recall that superiority trials
use the total, or intention-to-treat (ITT), population for
the primary analysis.) Many appeal to the PP population
in a non-inferiority trial because the more poorly run a
trial, the more likely an ITT analysis will show non-
inferiority. Consider a trial with a hopelessly flawed ran-
domization, where instead of creating two distinct treat-
ment groups (one set of subjects receiving the new
treatment and the other the active comparator), the ran-
domization scheme actually created two ‘blended’
groups, each composed of half subjects receiving the
new treatment and half receiving the active comparator.
If this trial were testing for superiority, the test would,
with high probability, correctly find no difference
between the groups. As a non-inferiority trial, however,
such a flawed trial would be very likely to incorrectly
demonstrate non-inferiority. This trial as described is an
extreme example of the importance of assay sensitivity,
in that a trial with such a flawed allocation scheme has
lost the ability to distinguish any true differences
between treatment groups that may exist, and is an
argument for why conventional wisdom favors showing
benefit in the PP population.
Others [4] (including the authors) disagree with that
opinion. Appeal to the dangers of sloppiness is not a
reason for using the PP population but rather a reason
for ensuring that a trial is well designed and carefully
monitored, with the primary analysis performed on an
ITT population. From a regulatory perspective, however,
both populations are of interest. The US and European
regulators are interested in success on both the ITT and
the PP populations. The EMA publication Points to
Consider on Switching between Superiority and Non-
inferiority [5] specifically states that a non-inferiority
trial must show non-inferiority in both the ITT and the
PP populations. The US regulators [6] cite ‘significant
concerns with the possibility of informative censoring’
in an ‘as-treated’ or PP, analysis, and advise investigators
to plan both types of analyses in their non-inferiority
trials. They go on to state that discrepancies between
the two types of analyses will require ‘close examina-
tion’, words that no investigator wants to hear from
regulators.
An investigator may also have several choices for the
comparator arm in a non-inferiority trial, but it must be
a ‘fair fight’. One example of an unfair control would be a
comparator with a dose that is lower than optimal.
Another stems from biocreep. Suppose an earlier trial
found drug A to be clearly better than placebo, then sev-
eral years later, drug B is found non-inferior to drug A in
a trial with a large non-inferiority margin. Drug C is then
compared to drug B, again with a large non-inferiority
Figure 2 Possible outcomes of a non-inferiority trial.
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example of biocreep; at each step, the new drug has been
shown to be not unacceptably worse than the previous.
Hence, a comparison of a new drug with drug C may not
be fair, because drug C may in fact be less effective than
drug A and, if the margins were too big, even less effec-
tive than placebo. We mention this situation again below
when talking about ‘constancy.’
Sufficient data need to be available to allow calcula-
tion of the non-inferiority margin for the same disease
and endpoint. The FDA Guidance [6] does allow, how-
ever, that the active control need not be approved for
the indication of interest in the non-inferiority trial if
these data exist.
Choosing the margin, conceptually
Having agreed to analyze both the ITT population and
some version of a PP population, and having selected the
appropriate active control, an investigator next must
select the non-inferiority margin and method of analysis.
One approach would be to ask clinicians or patients to
consider what degree of efficacy they would be willing to
sacrifice in exchange for the potential benefits offered by
the new treatment. A panel of clinical experts with
knowledge of existing treatment options and underlying
disease may be able to consider trade-offs on the level of
the patient population, and could propose a plausible
non-inferiority margin. Patient groups could perhaps
provide more insight into trade-offs that potential
patients might be willing to make for a product with ben-
efits such as an improved dosing schedule or fewer side
effects. Such an argument, seeking guidance from the
oracle of clinical judgment or patient experience, may be
appealing from the perspective of some physicians, but
such a Delphic method may have limited success in a
scientific or regulatory setting, which could require justi-
fication of expected treatment effects and variability.
Two more formal approaches to the margin and ana-
lysis are the putative placebo (also known as synthesis
method) and the 95-95 approach in Rothmann [7,8].
The 95-95 method starts by calculating M1,t h ee n t i r e
effect of the active control relative to placebo. This calcu-
lation typically uses meta-analytic methods with data
from previous studies, as we describe below, to obtain a
95% CI around the estimated difference between the
active control and placebo. A conservative estimate of
this difference, the lower limit of that CI, is then used as
M1. Next, a smaller margin, M2, is specified in order to
preserve some predetermined fraction of the estimated
active control effect, for example, 50 or 75%. We can
interpret M2 as the largest loss of effect (inferiority) that
would be clinically acceptable when comparing the test
drug to the active control. These definitions of M1 and
M2 come from the notation used in the FDA Guidance
document, which we discuss in the next section. Having
established the margin M2, a non-inferiority trial using
the fixed-margin approach is successful if the lower limit
o ft h e9 5 %C Ia r o u n dt h ed i f f e r e n c eb e t w e e nt h en e w
treatment and the active control lies above that margin.
The synthesis method, by contrast, does not require
specification of a specific margin or active control effect
[6,9]. This approach specifies a threshold for the desired
fraction of the effect of the active control that is retained
by the new treatment. Thus, the test of the non-inferior-
ity hypothesis in this type of analysis is based on a combi-
nation of the estimate and standard error (SE) for the
comparison of active control with placebo, which is not
observed in the current study, and the estimate and SE
for the comparison of the new treatment with the active
control in the current study. This method assumes that
the effect of the active control remains reasonably con-
stant over time, or that if the effect does diminish over
time (as a result, for example, of improved concomitant
therapies), such a modified effect can be estimated. See
Rothmann et al. [7] for insights into modeling either the
active control effect or its variability, and the papers by
Snappin and Jiang [10,11] for a unified approach to both
the fixed-margin and synthesis approach, which
addresses the assumptions of assay sensitivity and con-
stancy, and their implications on the Type I error rate.
We amplify these concepts below in the section on tech-
nical issues.
Regulatory perspectives
In March 2010, the Centers for Drug Evaluation and
Research (CDER) and Biologics Evaluation and Research
(CBER) of the US FDA issued a draft Guidance for Indus-
try on non-inferiority trials [6]. FDA Guidance docu-
ments represent the Agency’s current thinking on a wide
variety of topics in the drug development process, includ-
ing clinical issues, statistics, manufacturing, safety, and
labelling. This Guidance opens with an introductory
overview of non-inferiority trials. It then provides a care-
ful discussion of statistical issues, including methods for
determining an appropriate non-inferiority margin, and
closes by addressing questions through illustrative exam-
ples from recent submissions. Much of the philosophy
underlying this Guidance deals with the concern of the
FDA that in a trial without a placebo group (or more
generally, an untreated control), failure to find a differ-
ence between the new treatment and the active control
may actually mean that neither would have been better
than placebo. Thus, one way to look at the Guidance is
to consider it an attempt to ensure that a study that con-
cludes ‘non-inferiority’ has identified a treatment that is
superior to placebo.
The Guidance provides useful notation, which we have
adopted for our discussion in this paper. As described
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control has relative to placebo, and M2 to denote the
largest loss of effect (inferiority) that would be clinically
acceptable when comparing the test drug with the active
control.
The effect M1 is calculated from historical informa-
tion; it is not measured directly in a non-inferiority trial
(unless the trial includes a third arm, either a placebo or
no treatment). Nevertheless, the assumed advantage of
the active control over placebo must also be present in
the current study, even if the advantage is not directly
observed. We will discuss this assumption, known as
‘assay sensitivity’, in greater detail below.
The Guidance notes that in certain settings, it may be
reasonable to demonstrate only non-inferiority to the
M1 margin. Such a result shows that the test drug has a
non-zero effect, but that effect may not be clinically
meaningful. The smaller margin, M2, tightens the con-
nection between the test drug and the active control,
allowing a claim of non-inferiority only if the test drug
has not lost ‘too much’ of the effect of the active con-
trol. The Guidance states:
‘...a successful non-inferiority study shows rigorously
that the test drug has an effect greater than zero if it
excludes a NI margin of M1, so long as M1 is well
chosen and represents an effect that the control
drug actually would have had (versus a placebo, had
there been a placebo group). It can also show that
the test drug had an effect greater than some frac-
tion of the control drug effect, depending on the M2
that is used.’ ([6], page 12, section III.B).
Although non-inferiority trials are often conceptually
desirable, operational difficulties may plague the process
of choosing the margin, either because of insufficient
data to support a selected margin or a calculated margin
that leads to an impractical sample size. The Guidance
briefly discusses alternative designs that may be prefer-
able in these situations, including add-on studies, care-
fully selected patient populations, or randomized
withdrawal studies.
T h em a i nf o c u so ft h eG u i d a n c ec o m e si ns e c t i o nI V :
‘Choosing the non-inferiority margin and analyzing the
results of an NI trial’. Conceptually, the Guidance breaks
down the process into two steps: determining a reason-
able way of assessing the effect of the active control in
the current study, and then showing that the benefit of
the active control over the test drug in the current study
is no greater than the (assumed) entire effect of the active
control over placebo.
Once the margin has been selected, either from expert
opinion or from formal analytics of historical data, the
designers of the trial must determine how to analyze the
results of a non-inferiority study. The Guidance lays out
two possible approaches, which we have briefly intro-
duced above: the fixed-margin method (also known as
the double CI method or the 95-95 method [7,8]) and
the synthesis method. In the fixed-margin method, a
non-inferiority trial ‘succeeds’ if the lower limit of the
95% CI around the difference between the test drug and
the active control sits above the margin, either M1 or M2.
By contrast, the synthesis method does not define a
specific margin or effect of the active control based on
past trials. The Guidance says that ‘the synthesis method
is designed to directly address the question of whether
the test product would have been superior to a placebo
had a placebo been in the NI study [emphasis ours], and
also to address the related question of what fraction of
the active comparator’s effect is maintained by the test
product’ ([6], page 30). This approach combines the
effect of the test product that is observed in the non-
inferiority trial with an estimated control effect, from
either a single trial or a meta-analysis, to obtain a single
CI that is used to test the non-inferiority hypothesis
comparing the test product with the active comparator.
Considered another way, however, the synthesis method
could be applied (under the setting of 0% retention of
the active control effect) to test whether or not the test
product is better than placebo, assuming that an
unbiased estimate can be obtained of the active control
effect relative to placebo. The most important assump-
tion here is that the effect of the active control has
remained relatively constant (or can be modeled as dis-
cussed above) from the past into the current non-infer-
iority trial. This method is slightly more efficient in the
statistical sense (in terms of requiring a smaller sample
size to have the same statistical power), but is sensitive
to assumptions, and does not readily incorporate clinical
judgment into the definition of M2.
The Guidance concludes with responses to a series of
questions commonly asked about non-inferiority trials
and some examples. The questions concentrate on the
choice of margin and the distinction between M1 and
M2, the suitability of the active control, and options
when a non-inferiority trial is not feasible. The examples
illustrate the difference between the fixed-margin and
synthesis approaches to analysis, how to estimate the
active control effect in the absence of randomized pla-
cebo-controlled trials, a situation in which the historical
active control effect is so small that a non-inferiority
trial would be impractical, and a case in which the non-
inferiority criteria for success can be relaxed when two
studies provide consistent results.
By contrast, the EMA Guidance document on choos-
ing a non-inferiority margin [9] does not specify a
method for selecting the margin. Instead, the EMA
directs trial sponsors to use a combination of statistical
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could come from a Delphi-type approach asking experts
how much benefit over placebo they are willing to
forego by using the new product instead of the product
already shown to be effective. Alternatively, investigators
m a yc h o o s eam a r g i nu s i n gamore formal approach.
The document warns, however, that the margin selected
must be sufficiently small to ensure that the experimen-
tal therapy is better than placebo. In the words of the
EMA, ‘a minimal requirement for the decision making
process involved in interpreting data from a non-infer-
iority trial is that we must be confident that the test
product would have been shown to be efficacious if a
placebo-controlled trial had been performed’.
Choosing the margin, technically
Whether a Delphic method, the synthesis method, or the
95-95 approach is used, the first step in defining the non-
inferiority margin is to gather all relevant information
about the effect of the active control. For the Delphic
method, ‘all relevant information’ may reside in the minds,
the experience, and the judgment of expert clinicians. For
the synthesis and 95-95 methods, ‘all relevant information’
comprises the set of data addressing the magnitude of the
effect of the control treatment compared with placebo.
Both of these latter methods may use the same approach
to identify the effect of the control relative to placebo.
The first 95% (or how does the control compare with
placebo)
As described above, the purpose of the first 95% in the
95-95 method is to calculate the effect size for the con-
trol group that gives a reasonable assurance of being no
less than the true effect size. The philosophy is that cal-
culating the 95% CI for the estimated effect size, and
then choosing the lower end of that interval gives 95%
confidence that the true effect size for the control inter-
vention relative to placebo is at least as great as the cal-
culated effect size. Having accepted this principle as the
path to calculation, the next decision is what data to use
to compute that CI. The FDA Guidance suggests apply-
ing meta-analytic techniques to calculate the estimated
effect size and therefore the lower limit of the CI. For
convenience in exposition, we discuss here binary out-
comes; much of the discussion is relevant to other types
of outcomes as well.
Meta-analysis is a set of methods used to combine
data from a group of studies to obtain an estimate of a
treatment effect. Thus, the first step in performing a
m e t a - a n a l y s i si st oc o l l e c tt h eg r o u po fs t u d i e st ou s e .
When designing a non-inferiority trial, under ideal con-
ditions the investigator would select a set of studies that
includes only randomized trials comparing the control
intervention with placebo. The patient population
should be similar to the population being studied in the
non-inferiority trial being planned; the outcomes studied
in the trials should be the same as that planned; the
control regimen (intervention and dose) should be the
same as the regimen to be used in the new trial; and the
current standard of care should be the same as the stan-
dard of care in the previous trials (the ‘constancy’
assumption). Furthermore, the total population studied
in the set of trials under consideration should be suffi-
ciently large to produce a precisely estimated effect size.
In practice, limitations of a v a i l a b l ed a t ao f t e nf o r c e
investigators to compromise on some of these criteria.
The populations studied in the previous trials may differ
in important ways from the population planned for the
new trial. The former trials may not all have uniformly
compared the control intervention to placebo; some of
the trials may have used placebo whereas others may
have used standard of care, and some might have used
another active control. The outcome measures in the
previous trials may differ from the outcome in the trial
being designed. The intervention in the previous trials
might have used different doses from that being con-
templated in the new trial, or the relevant trials might
have used a drug from the same class as the planned
control, but not the same drug. And perhaps the most
vexing problem of all, because it is essentially unmeasur-
able, is the possibility that the standard of care has
changed in the years between the time of the previous
trials and the trial being planned. If so, a drug shown to
be effective in the past would perhaps not be shown to
be effective were the same trial performed today. Simi-
larly, if the trials under consideration for the meta-ana-
lysis were performed in countries with very different
standards of care from the country in which the non-
inferiority trial is to be performed, then the effect size of
the control may be different from what it would have
been in the country for which approval is being sought.
Assuming that the set of trials being considered do
not egregiously violate the ideal standards mentioned
above, the investigators are ready to produce an overall
estimate of the effect size.
A meta-analysis comparing treatment A with treat-
ment B starts with T randomized trials. If the primary
outcome of the trial is binary, for k =1 ,2 ,. . .T,t r i a lk
has sample sizes nkAand nkBwith SkAand SkBsuccesses,
respectively. The outcome of the Mantel-Haenszel (MH)
method is the pooled odds ratio across the T trials.
Each study can be represented by a 2 × 2 table with the
structure depicted in Table 1.
The odds ratio in each study (and table) is:
SkAFkB
SkBFkA
,
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 ORMH =
T
k=1
SkAFkB
nk
T
k=1
SkBFkA
nk
.
A method of Peto described by Yusuf [13] is also
often used in these settings. The method differs slightly
from the MH approach; however, for large sample sizes,
the two methods yield almost identical results.
In both the MH and the Peto methods, the logarithm
of the odds ratio under the null hypothesis is approxi-
mately normally distributed, with mean zero and var-
iance estimated from the observations. Both methods
weight studies according to their sample size, not the
size of the treatment effect within the study. In other
words, large studies have a large influence on the pooled
effect size, while small studies have a small influence on
the estimated effect.
Furthermore, if the true effect size is in fact identical in
all of the studies, then the MH test is the optimal proce-
dure, in the sense that it has the highest statistical power
of all possible unbiased tests. This property is often sub-
verted by saying that these tests require that the studies
have the same true effect size, or that they are ‘fixed
effects models.’ In fact, neither the MH nor the Peto
method requires identical effect sizes. The logical inter-
pretation of a meta-analysis using either of these meth-
ods is not that the true effect of the treatment is the
same in all situations, but rather that the overall estimate
obtained from a meta-analysis is the best estimate of the
treatment effect, averaged over all studies included.
The FDA Guidance suggests a preference for so-called
‘random-effects models’ in meta-analyses that will be used
to establish the margin in non-inferiority trials. These
models, in contrast to the MH and Peto approaches, make
very specific assumptions about the distribution of the
effect size across all potential studies. The standard
method, introduced by DerSimonian and Laird [14],
assumes that the effect size (which in the case of binomial
variables is the log odds ratio) comes from a normal distri-
bution with mean μ and variance s
2. This assumption
implies that the estimated pooled effect is a weighted aver-
age of the effect obtained in each study; in contrast to the
MH and Peto methods, the weights are a function both of
the sample sizes of the various studies and the closeness of
each within-study estimate to the estimates from the other
studies. As Petitti [15] points out, when results from stu-
dies are heterogeneous, random-effects models tend to
overemphasize the importance of small studies. Such
weighting may be inappropriate; small studies are often
conducted at a single center, and are more likely to be
subject to bias and less likely to have had rigorous check-
ing of data quality or the use of rigorous methods in study
conduct. See Teo et al. [16] for a discussion of a random-
effects meta-analysis on the use of magnesium, which led
to erroneous results. In that case, one small study, with
results quite different from other, larger, trials, dominated
the estimated effect size because the assumptions of the
random-effects model put undue weight on the small trial.
The typical presentation of a meta-analysis shows a
forest plot depicting the results of each trial, and then a
summary statistic showing the estimated effect. Having
completed this meta-analysis, the investigator calculates
the 95% CI and finds what FDA calls M1, the effect size
of the control therapy that will be assumed (Figure 3).
If the outcome is a time-to-event variable or a contin-
uous variable, the meta-analysis is typically performed
on the estimated hazard ratios or means, respectively.
Choice of M2: how much are we willing to lose?
As the EMA Guidance document stresses, both statistical
and clinical judgment should play into the choice of mar-
gin. M1 is calculated, as described above, as the lower
end of the 95% CI around the best estimate of the effect
size of the control group relative to placebo. This number
becomes the starting point for the determination of the
margin. The investigator must now ask how much of that
benefit is acceptable to lose if the new therapy is adopted.
The past experience of the investigators may allow them
to define the magnitude of a loss of efficacy that they
would be clinically willing to accept. By thinking through
a population of, for example, 100 cases, a clinician may
be able to quantify such judgments by considering what
might be an acceptable loss of efficacy compared with a
standard treatment.
Sometimes, investigators do not carry out such a for-
mal analysis; instead they figure out how much money
they can spend. From there, they determine the largest
trial that they can run, and justify the margin after the
fact. This (not exactly a secret) is what investigators often
do for superiority trials; the difference is that the purpose
of a superiority trial is to show benefit, and if the power
is too low for a given sample size, the trial is unlikely to
show superiority. In the looking-glass non-inferiority
world, however, the analogous action is to make the mar-
gin too big, increasing the chance of successfully demon-
strating non-inferiority of the new treatment.
Table 1 Illustration of a 2 × 2 table for the kth trial.
Treatment group Total
AB
Success SkA SkB Sk
Failure FkA FkB Fk
nkA nkB nk
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M1; however, when a drug is highly effective, losing half
its effect, even though it may still be better than pla-
cebo, may not be clinically acceptable (Figure 4). Con-
sider, for example, a childhood vaccine that prevents
96% of potential cases of disease. A new oral vaccine
that only prevents 48% of disease would still be much
more effective than placebo, but would hardly be attrac-
tive, even if less painful to the child than a shot. Thus,
highly effective products for serious diseases should gen-
erally be evaluated in trials in which the margin pre-
serves a large proportion of M1. In other settings, if the
benefits of the new product, in terms of adverse events,
ease of administration, and cost are very great, investiga-
tors might be willing to forego an even higher percen-
tage of M1.
The second 95% (or, is the new product non-inferior to
the old?)
Having selected M1 (from the first 95%) and M2 (from
judgment), the trial begins. At the end of the trial a 95%
CI is calculated from the observed data. If that interval
sits completely above the prespecified -Δ,t h et r i a lh a s
shown non-inferiority. In fact, we can refer back to
Figure 2 and see how the confidence limit compares
with the limits shown in the figure.
Sample size
T h es a m p l es i z ef o ran o n - i n f e r i o r i t yt r i a li sc a l c u l a t e d
to satisfy the following equation:
Pr[(ˆ θT − ˆ θC) − 1.96 SE(ˆ θT − ˆ θC) > − |θT − θC = γ] ≥ Desired power
In words, this means that the sample size must be
large enough so that the probability is sufficiently high
that the lower bound of the 95% CI for the estimated
difference between the treated group and the control
group (ˆ θT − ˆ θC) is greater than the margin, -Δ, when the
true difference between the groups, θT-θC,i sg.
Sample size for a non-inferiority trial is usually calcu-
lated under the assumption that the experimental agent
and control treatment have equal effects, that is, when g
is assumed to be zero. Under the assumption that the
new treatment is a little better, as is often the case for a
new product, the required sample size decreases
considerably.
Consider, for example, a comparison of two propor-
tions as illustrated in Table 2. For a fixed margin, set to
Figure 3 A forest plot and M1.
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t a b l ep r e s e n t st h ea p p r o x i m a t es a m p l es i z er e q u i r e d
assuming equal treatment effects, a small (5%), and a
larger (10%) benefit for the experimental agent.
As an example of how to read the table, consider the
row in bold font, in which the true proportion in the
active control is 50%. The smallest proportion that
would be considered not non-inferior is 45% (a loss of
10% from the active control effect). Assuming that the
proportions in the new treatment and the active control
are equal, the total sample size required would be
approximately 2,100 per group. If, however, the new
treatment actually provided a 5% benefit over the active
control, corresponding to a true proportion of 52.5%,
t h er e q u i r e ds a m p l es i z ew o u l db ea p p r o x i m a t e l y1 , 0 0 0
per group to show non-inferiority. That is, with a
sample size of 1,000 per group, if the true proportion in
the active control is 50% and the true proportion in the
new treatment is 52.5%, then the probability is 90% that
the lower bound of the CI is above -5%. A 10% benefit,
corresponding to a proportion of 55% in the new treat-
ment, would require a sample size of just over 500 per
group to show non-inferiority.
Assuming a small benefit of the experimental agent
compared with the active control cuts the sample size
required roughly in half; if the larger benefit is more
realistic, the sample size is roughly a quarter of that
required for the assumption of equal treatment effect.
These are still, however, relatively modest improve-
ments over the effect of active control, and although the
sample size reductions when assuming these benefits are
non-trivial, they are not so large as to suggest switching
Figure 4 M2 as a fraction of M1.
Table 2 Approximate sample sizes required for non-inferiority comparison of proportions
True proportion in active control Non-inferiority bound using 10% margin Approximate sample size per group assuming 1:1
randomization to new treatment and control required
under:
Equal effects 5% benefit 10% benefit
0.1 0.09 19,200 8,725 5,050
0.2 0.18 8,500 3,900 2,250
0.3 0.27 4,970 2,260 1,300
0.4 0.36 3,200 1,450 825
0.5 0.45 2,100 1,000 550
0.6 0.54 1,440 640 360
0.7 0.63 930 405 225
Sample sizes calculated using Pass 2008 methods for non-inferiority tests of two independent proportions, using the Z statistic with continuity correction and
pooled variance, with a target power of 90% and a level of 0.025.
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size required for a superiority trial to demonstrate the
small benefit would be nearly 10 times larger than
required for the non-inferiority trial, and around four
times as large for the larger effect.
Concerns about non-inferiority trials
Non-inferiority trials have a host of complications. A ser-
ious concern, as briefly described above, is assay sensitiv-
ity, the ability of a trial to distinguish an effective therapy
from one that is not effective, and the issues differ for
non-inferiority trials and superiority trials. A superiority
trial that lacks assay sensitivity will probably show that
the new therapy does not have a statistically significant
benefit over control, as the trial will be unable to declare
efficacy. By contrast, a non-inferiority trial without assay
sensitivity may generate a positive result (that is, it may
show evidence of non-inferiority) if it shows no differ-
ence between the treatment groups, as this would lead to
a conclusion of non-inferiority. Unlike superiority trials,
non-inferiority trials have no internal check on assay sen-
sitivity. (The check in a superiority trial is showing that
the tested intervention is superior to control.) The EMA,
in an effort to mitigate this problem, has suggested that
non-inferiority trials, wherever possible, include a pla-
cebo arm to allow a direct comparison of both the active
control and experimental agent with placebo. (Note that
the study may be the new drug, the old drug, and the pla-
cebo, all on a background of standard of care.) In many
cases, such a trial is not ethically acceptable. That is, ran-
domizing participants to placebo may not be appropriate
when an existing therapy with a proven survival benefit
exists (for example, in cancer), whereas in other cases
(for example, pain relief) a three-arm trial could work
well.
Another concern specific to non-inferiority trials per-
tains to the evolving standard of care, as discussed above.
Consider the situation with an existing drug (drug A) that
is approved for the treatment of an infectious disease on
the basis of a placebo-controlled trial. Now suppose that a
company applies to regulatory agencies for approval of a
new treatment (drug B) using a non-inferiority design with
drug A as the active control. Suppose that the trial is ‘suc-
cessful,’ that is, drug B is shown to be non-inferior to drug
A with respect to the cure rate. Presumably, if drug B has
some advantages, such as fewer side effects or an
improved dosing schedule, it will then become the stan-
dard of care. Then suppose the next company applies for
approval of another drug (drug C) using a non-inferiority
comparison against drug B. If drug A were actually not
superior to placebo in the first trial, it could be fairly easy
to show that each new drug is non-inferior to the active
control, even when none is any better than placebo. In
most cases, the issue with standard of care is not as dire as
this illustration might suggest, as the point estimates could
show a positive effect even if the margin allowed some
loss of efficacy, but the concern is valid. As mentioned ear-
lier, this change in effect is termed ‘biocreep’ in the case of
drugs, and ‘technocreep’ in the case of devices.
Further, in the case of infectious diseases, the organisms
themselves might evolve, leaving us with the possibility of
true biological ‘biocreep’. That is, over time, organisms
develop resistance to earlier drugs in the pharmacopoeia,
meaning that each new drug is being compared with an
active control that might be becoming less and less effec-
tive against a strengthening infectious agent. Here, bio-
creep represents actual biological change in the organism.
What is usually called ‘biocreep’ is more precisely ‘virtual
biocreep,’ w h e r ee a c hs u c c e s s i v ep r o d u c tm a yb eal i t t l e
bit less effective than the previous product [17,18].
But what if a non-inferiority trial cannot be
performed?
As alluded to above, a variety of reasons may render a
non-inferiority trial unfeasible. A rigorously calculated
m a r g i nc o u l dy i e l das a m p l es i z et h a tc a n n o tb es u p -
ported financially or by the potential study population.
The EMA Guidance specifically warns investigators not
to increase their non-inferiority margin when the scienti-
fically derived margin produces an impractically large
sample size. Sometimes the necessary data may not exist
(or may not be available to a new investigator) to calcu-
late a margin as carefully as desired; or the treatment
landscape may have changed so much since the historical
data were collected that it is unclear what active control
to use and whether or not that control really does show a
benefit over placebo; or the trial may be in a therapeutic
area in which well-known effective treatments do not
always beat placebo (for example, depression), making it
difficult to argue for the assay sensitivity required to plan
a non-inferiority trial. Although challenging, such cir-
cumstances offer opportunity to the creative trialist (and
statistician).
Conclusions
A non-inferiority trial is reasonable when a new treat-
ment has some property sufficiently favorable that physi-
cians, and their patients, would be willing to sacrifice
some degree of benefit relative to an already approved
therapy. The advantage could be reduced cost, improved
ease of use or dosing schedule (monthly versus weekly
injections), simpler storage (not requiring refrigeration),
or an improved safety profile. The benefit given up in
exchange for these advantages, however, should not be so
large that patients and physicians are not willing to use
the new product. As discussed in the vaccine example
above, an oral formulation that loses half the protection
provided by an injection would not be a viable product.
Schumi and Wittes Trials 2011, 12:106
http://www.trialsjournal.com/content/12/1/106
Page 11 of 12T h ec h o i c eo ft h en o n - i n f e r i ority margin and how much
of the existing treatment effect to preserve incorporates
in some sense these other aspects of treatment ‘viability’.
From the perspective of regulators in the USA, how-
ever, success in a non-inferiority trial cannot formally
incorporate these multi-faceted aspects; it simply is not
the way their regulations are written at this point. The
M2 does provide some room for flexibility by varying the
proportion of the active control effect that is preserved.
For serious diseases with known and highly effective
treatments, any new product would need to preserve a
large amount of the known treatment effect to be consid-
ered successful. In other settings (mild headache, for
example), a more modest preservation of effect might
still be of interest. In selecting M2, investigators and drug
developers should consider consulting with patients to
ascertain whether a margin acceptable to regulators is
too large to be acceptable to patients.
Expanding the primary endpoint into a composite
incorporating efficacy and quality of life, efficacy and
cost, or efficacy and safety, would be complicated. We
advocate considering whether to revise the relevant legis-
lation to modify the regulations so that regulators are leg-
ally able to take into account multiple dimensions of a
new product. The resulting analyses would become ever
more complicated, but the regulatory decisions would be
more nuanced and ultimately better for the public health.
At present, however, success in a non-inferiority trial in
the USA depends upon success in the primary outcome
measure, not on other aspects of benefit, such as safety,
and regulatory success using non-inferiority trial designs
may require completion of more than one such trial.
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